The most clinically advanced work concerns PHD inhibitors, four of which are now in trials for anaemia treatment via upregulation of EPO or selective metabolism.18,25 Various lines of evidence indicate that PHD inhibition is efficacious in terms of EPO upregulation. The gene discussed is EPO; the disease is anemia (phenotype).